The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
=== Canada === During his visit to North America in August 1941, Howard Florey approached the Connaught Laboratories at the University of Toronto, where he met with the director, R. D. Defries, and Ronald Hare. Florey was rebuffed; Defries argued that the laboratories did not have the space, and he expressed his belief that constructing facilities to culture penicillin would be a waste as it would soon be synthesised. The results of clinical trials caused a change of heart, and in August 1943 the Canadian government asked the Connaught Laboratories to initiate mass production of penicillin. The Spadina Building was purchased by the University of Toronto for the purpose, and refurbished at a cost of Canadian $1.2 million (equivalent to Canadian $22 million in 2025), split equally between the university and the government. Penicillin was initially cultured in 200,000 bottles occupying 740 square metres (8,000 sq ft) of air-conditioned laboratory space. Production was switched to the deep submergence method in November 1945.
America's Taco Shop – a restaurant chain with locations only in Arizona. Baja Fresh – a chain of fast-casual Tex Mex restaurants in the United States, Portugal and Kuwait. Blimpie – an American submarine sandwich chain with locations in the United States and Kuwait Cereality – a chain with stores in Texas, West Virginia, Minnesota and Ohio; also formerly had stores in Illinois. Cold Stone Creamery – an ice cream parlor restaurant chain with stores in Bahrain, Canada (partnership with Burger King/Tim Hortons from 2008 to 2014 now terminated), China, Denmark, Egypt, India, Indonesia, Japan, Kuwait, Mexico, Nigeria, Oman, Qatar, South Korea, Taiwan, United Arab Emirates, United States, Philippines, Kenya, Bangladesh, Pakistan, Finland, Jordan, Norway, Saudi Arabia, Sweden, Vietnam, Singapore and Lebanon Frullati Cafe & Bakery – chain with stores in Kuwait and the United States. Grabbagreen – a chain of restaurants offering healthy foods and smoothies. Great Steak – a restaurant chain with locations in Canada, Mexico, Kuwait and the United States. Founded 1982; formerly "Great Steak & Potato Company". In 2000, it had 225 locations. Sold to Kahala Brands in 2004; expansion planned into South Korea. Johnnie's New York Pizzeria – restaurant chain with stores in California, Florida, Oregon, and Texas. Kahala Coffee Traders (California, Utah) La Salsa – a chain of fast-casual Tex Mex restaurants in the United States Maui Wowi Hawaiian – chain with stores in the United States, Mexico, Saudi Arabia and the United Arab Emirates.
== Mutations == Mutations or deletions in the AZF genes are associated with inability or lessened ability to create sperm. It may cause azoospermia (not having any measurable level of sperm in semen). Deletions in the USP9Y gene, which is located within AZF1, are usually associated with inability to form sperm.
Frank and John Kirby and their associate Rodney Lester were pioneers in pharmacy automation and small-object counting technology. In 1967, the Kirbys invented a portable digital tablet counter to count tablets and capsules. With Lester, they formed a limited company. In 1970, their invention was patented and put into production in Oldham, England. The tablet counter aided the pharmacy industry with time-consuming manual counting of drug prescriptions. As well as automating labour, early counting machines created consistent and predicable standards for speed and accuracy in medication dispensing. These improvements motivated further innovation aimed at improving safety, efficiency, and cost-effectiveness across the pharmaceutical industry for a wide array of tasks. Today, modern pharmacies choose from a diverse suite of automation technologies specific to their particular workflows.
In the investigation of the infrared spectrum of the Galactic Center of the Milky Way, monoxide vibrations of iron carbonyls in interstellar dust clouds were detected. Iron carbonyl clusters were also observed in Jiange H5 chondrites identified by infrared spectroscopy. Four infrared stretching frequencies were found for the terminal and bridging carbon monoxide ligands. In the oxygen-rich atmosphere of the Earth, metal carbonyls are subject to oxidation to the metal oxides. It is discussed whether in the reducing hydrothermal environments of the prebiotic prehistory such complexes were formed and could have been available as catalysts for the synthesis of critical biochemical compounds such as pyruvic acid. Traces of the carbonyls of iron, nickel, and tungsten were found in the gaseous emanations from the sewage sludge of municipal treatment plants. The hydrogenase enzymes contain CO bound to iron. It is thought that the CO stabilizes low oxidation states, which facilitates the binding of hydrogen. The enzymes carbon monoxide dehydrogenase and acetyl-CoA synthase also are involved in bioprocessing of CO. Carbon monoxide containing complexes are invoked for the toxicity of CO and signaling.
Sources: en.wikipedia.org
== Interactions == The enzymes in NexoBrid inhibit the liver enzymes CYP2C8 and CYP2C9 when ingested. These are involved in the breaking down of a number of drugs, including amiodarone, chloroquine, ibuprofen, and warfarin. It is not known whether this mechanism has any clinical relevance.
In December 2022, the company announced initial phase 1 clinical trial results for its flu vaccine patch. In 2023, Vaxess and AstraZeneca announced the development of a skin patch for mRNA vaccines focused on pandemic flu. In May 2024, Vaxess announced $12 million in funding and named Rachel Sha as CEO of the company. In May 2025, Vaxess announced $9 million in funding to advance its work in GLP-1, and . In June, the company presented new clinical data on the capability of its drug delivery patch to deliver semaglutide.
== Condensation polymerization == Step-growth polymerization and condensation polymerization are two different concepts, not always identical. In fact polyurethane polymerizes with addition polymerization (because its polymerization produces no small molecules), but its reaction mechanism corresponds to a step-growth polymerization. The distinction between addition polymerization and condensation polymerization was introduced by Wallace Carothers in 1929, and refers to the type of products, respectively:
=== Soviet Lunar sample return and robotic rovers === In late 1970 Luna 16 was launched by the Soviet Union, and became the first uncrewed probe to return a sample from the Moon. This was followed by Luna 20 and Luna 24 in subsequent years. The Soviet Union was also able to successfully land the first robotic rover on the Moon in 1970, followed by another in 1973, with the Lunokhod missions. These missions demonstrated continued Soviet willingness to compete with the US in the space race despite having lost the manned Moon landing aspect of the space race.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.